Premium
Fabrication of galactosylated chitosan–5‐fluorouracil acetic acid based nanoparticles for controlled drug delivery
Author(s) -
Yu CuiYun,
Li NaMei,
Yang Sa,
Ning Qian,
Huang Can,
Huang Wen,
He ZiNing,
He DongXiu,
Tan XiangWen,
Sun LiChun
Publication year - 2015
Publication title -
journal of applied polymer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.575
H-Index - 166
eISSN - 1097-4628
pISSN - 0021-8995
DOI - 10.1002/app.42625
Subject(s) - nanoparticle , chitosan , drug delivery , acetic acid , nuclear chemistry , conjugate , fourier transform infrared spectroscopy , chemistry , prodrug , drug carrier , materials science , nanotechnology , chemical engineering , organic chemistry , biochemistry , mathematical analysis , mathematics , engineering
In this study, a novel type of macromolecular prodrug, N ‐galactosylated chitosan (GC)−5‐fluorouracil acetic acid (FUA) conjugate based nanoparticles, was designed and synthesized as a carrier for hepatocellular carcinoma drug delivery. The GC–FUA nanoparticles were produced by an ionic crosslinking method based on the modified ionic gelation of tripolyphosphate with GC–FUA. The structure of the as‐prepared GC–FUA was characterized by Fourier transform infrared and 1 H‐NMR analyses. The average particle size of the GC–FUA nanoparticles was 160.1 nm, and their drug‐loading content was 21.22 ± 2.7% ( n = 3). In comparison with that of the freshly prepared nanoparticles, this value became larger after 7 days because of the aggregation of the GC–FUA nanoparticles. An in vitro drug‐release study showed that the GC–FUA nanoparticles displayed a sustained‐release profile compared to 5‐fluorouracil‐loaded GC nanoparticles. All of the results suggest that the GC–FUA nanoparticles may have great potential for anti‐liver‐cancer applications. © 2015 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2015 , 132 , 42625.